AIM ImmunoTech Inc. converted approximately $400,000 of its outstanding Promissory Note into 1,749,434 shares of common stock at an average conversion price of $0.228 per share through exchange agreements with Streeterville Capital, LLC. This transaction was approved by stockholders at a special meeting on July 15, 2026, and executed between September 8 and 9, 2026. The company operates in the biotechnology industry, focusing on immunotherapy treatments.
